Thetis Awarded $1.9M NIH Grant to Advance TP-252 into Clinical Trials for Ulcerative Colitis

Thetis Awarded $1.9M NIH Grant to Advance TP-252 into Clinical Trials for Ulcerative Colitis
Thetis Pharmaceuticals recently received a $1.9 million fast-track Small Business Innovation Research grant from the National Institutes of Health (NIH) to help advance the development of TP-252, an investigational oral therapy for ulcerative colitis (UC), into clinical trials. TP-252 is a derivative of eicosapentaenoic acid free fatty acid (EPA-FFA), which has been shown to help reduce relapse in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *